Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

Here we report the design and production of an antibody-fluorophore conjugate (AFC) as a non-toxic model of an antibody-drug conjugate (ADC). This AFC is based on the conjugation of dansyl sulfonamide ethyl amine (DSEA)-linker maleimide on interchain cysteines of trastuzumab used as a reference antibody. The resulting AFC was first characterized by routine analytical methods (SEC, SDS-PAGE, CE-SDS, HIC and native MS), resulting in similar chromatograms, electropherograms and mass spectra to those reported for hinge Cys-linked ADCs. IdeS digestion of the AFC was then performed, followed by reduction and analysis by liquid chromatography coupled to mass spectrometry analysis. Dye loading and distribution on light chain and Fd fragments were calculated, as well as the average dye to antibody ratio (DAR) for both monomeric and multimeric species. In addition, by analyzing the Fc fragment in the same run, full glyco-profiling and demonstration of the absence of additional conjugation was easily achieved. As for naked antibodies and Fc-fusion proteins, IdeS proteolytic digestion may rapidly become a reference analytical method at all stages of ADC discovery, preclinical and clinical development. The method can be routinely used for comparability assays, formulation, process scale-up and transfer, and to define critical quality attributes in a quality-by-design approach.

[1]  A. Beck,et al.  Fourth World Antibody-Drug Conjugate Summit , 2012, mAbs.

[2]  Christian Bailly,et al.  The next generation of antibody-drug conjugates comes of age. , 2010, Discovery medicine.

[3]  M. Dorywalska,et al.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.

[4]  P. Carter,et al.  8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. , 2013, mAbs.

[5]  W. J. Galush,et al.  Profiling antibody drug conjugate positional isomers: a system-of-equations approach. , 2012, Analytical chemistry.

[6]  L. Björck,et al.  Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. , 2004, Biochemistry.

[7]  S. Alley,et al.  Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. , 2013, Current opinion in chemical biology.

[8]  William Bauta,et al.  Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates , 2012, Cancer Chemotherapy and Pharmacology.

[9]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[10]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[11]  Aditya A Wakankar,et al.  Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.

[12]  François Debaene,et al.  Analytical characterization of biosimilar antibodies and Fc-fusion proteins , 2013 .

[13]  P. Burke,et al.  A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.

[14]  P. Parren,et al.  In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap , 2013, mAbs.

[15]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[16]  A. Beck,et al.  World Antibody Drug Conjugate Summit Europe , 2011, mAbs.

[17]  John F. Valliere-Douglass,et al.  Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. , 2012, Analytical chemistry.

[18]  M. Sliwkowski,et al.  Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.

[19]  D. Suckau,et al.  Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques , 2013, mAbs.

[20]  Michael M C Sun,et al.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.

[21]  W. Atkins,et al.  Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates , 2012, mAbs.

[22]  Huijuan Li,et al.  Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry , 2013, mAbs.

[23]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[24]  R. Huber,et al.  Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Asher Mullard,et al.  Maturing antibody–drug conjugate pipeline hits 30 , 2013, Nature Reviews Drug Discovery.

[26]  I. Bernstein,et al.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.

[27]  A. Beck.  Glycosylation Engineering of Biopharmaceuticals , 2013, Methods in Molecular Biology.

[28]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[29]  Sheng Yin,et al.  Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. , 2013, Analytical chemistry.

[30]  A. Beck,et al.  Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. , 2013, Methods in molecular biology.

[31]  N. Bihoreau,et al.  Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry. , 2011, Analytical biochemistry.

[32]  Hongcheng Liu,et al.  Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. , 2010, Analytical chemistry.

[33]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[34]  L. Björck,et al.  IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G , 2002, The EMBO journal.